A5100670869- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Monoclonal and Polyclonal Antibodies Research
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Glycosylation and Glycoproteins Research
- Esophageal Cancer Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Gastrointestinal Tumor Research and Treatment
- Multiple Myeloma Research and Treatments
- Molecular Biology Techniques and Applications
- Colorectal Cancer Surgical Treatments
- Mechanisms of cancer metastasis
Natera (United States)
2018-2025
The Royal Free Hospital
1996
Roland Hill (United Kingdom)
1996
University College London
1996
Novel sensitive methods for detection and monitoring of residual disease can improve postoperative risk stratification with implications patient selection adjuvant chemotherapy (ACT), ACT duration, intensity radiologic surveillance, and, ultimately, outcome patients colorectal cancer (CRC).To investigate the association circulating tumor DNA (ctDNA) recurrence using longitudinal data from ultradeep sequencing plasma cell-free in CRC before after surgery, during ACT, surveillance.In this...
PURPOSE Novel sensitive methods for early detection of relapse and monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, ultimately outcome patients with bladder cancer. We addressed the prognostic predictive ultra-deep sequencing cell-free DNA in before after cystectomy during chemotherapy. PATIENTS AND METHODS included 68 localized advanced Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor...
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical ctDNA in stage II-IV CRC (n = 1,039). In this cohort, a median follow-up 16.74 months (range 0.49-24.83...
Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions patient management stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored added benefits serial analysis: adjuvant chemotherapy (ACT) growth rates.We recruited 168 patients with treated curative intent at Danish Spanish hospitals between 2014 2019. To quantify in plasma samples...
PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic [mCRC]) relapse postresection. The efficacy postoperative systemic treatment is limited in this setting. Thus, these would greatly benefit from the use a reliable prognostic biomarker, such as circulating tumor DNA (ctDNA) to identify minimal or molecular residual disease (MRD). PATIENTS AND METHODS We analyzed cohort 112 mCRC who had undergone metastatic resection curative intent part PREDATOR clinical trial....
Abstract Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, despite recent advancements, most patients die of their disease. Although immune checkpoint blockade became part the standard-of-care for with metastatic G/GEJ cancers, its efficacy impact on tumor microenvironment (TME) in early disease remain largely unknown. We hypothesized higher neoadjuvant immunotherapy plus chemotherapy nonmetastatic cancer. In phase 2 PANDA trial, previously untreated resectable...
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated association circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated a 23-month median follow-up, including 2,240 patients stage II-III colon or IV CRC, reinforces prognostic value ctDNA positivity during MRD window significantly inferior disease-free survival (DFS;...
9 Background: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) has the potential to select patients who may benefit more from standard-of-care (SOC) adjuvant chemotherapy (ACT) by accurately assessing recurrence-risk post-surgery and evaluating ACT efficacy. Here we present an analysis GALAXY study, observational study monitoring MRD, association of ctDNA dynamics with a short-term clinical outcome Methods: A personalized tumor-informed assay (Signatera bespoke...
Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA esophagogastric cancers (EGC) is less characterized could identify high-risk who have been curative intent.In this retrospective analysis real-world data, levels were analyzed the preoperative, postoperative, surveillance settings EGC using a personalized multiplex polymerase chain reaction-based next-generation sequencing assay. Plasma...
Abstract Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. Experimental Design: We present full follow-up results (median follow-up: 68 months) from a previously described cohort neoadjuvant chemotherapy (NAC)-treated who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed evaluation 153 samples collected...
The prognostic role of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection and its utility for postsurgical risk stratification has been reported in colorectal cancer. In this study, we explored the use ctDNA-based MRD patients with liver metastases (CLM), whom survival benefit adjuvant chemotherapy (ACT) after surgical resection remains unclear.
11 Background: Timely detection of recurrence, as well identification patients at high risk recurrence after surgery and completion adjuvant therapy, are major challenges in the treatment colorectal cancer (CRC). Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for with minimal residual disease (MRD) recurrence. The objective this prospective, multicenter study was to determine whether serial postsurgical ctDNA could identify provide an assessment therapy efficacy...
102 Background: Numerous studies have shown the clinical utility of ctDNA, a non-invasive biomarker to detect MRD and stratify CRC patients who are more likely relapse. We present an analysis detection in from prospective multicentre UK study, were monitored pre- post-surgery before adjuvant chemotherapy (ACT). Methods: The study recruited diagnosed with stage II-III (n=122), including subset rectal underwent tri-modality treatment (TMT). All had their primary tumor resected 56% (68/122)...
4028 Background: After surgery, patients (pts) with LAR G/GEJ ADENOCA have a high recurrence risk despite Tx. Here, we investigate the ability of ctDNA to predict Tx response and improve stratification in sub-cohort pts from PLAGAST prospective study (NCT02674373). Methods: Plasma samples were prospectively collected at baseline (before neoadjuvant therapy (NAT)/before surgery for NAT-naive pts), during-NAT, post-NAT, post-surgery within 2-12 weeks, before adjuvant [molecular residual...
Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of remission. Current techniques for MRD assessment involve bone marrow (BM) aspirate sampling, which is invasive, subject to sample variability and limited spatial heterogeneity. We compared performance a...
A majority of patients with metastatic colorectal cancer (mCRC) experience recurrence post curative-intent surgery. The addition adjuvant chemotherapy has shown to provide limited survival benefits when applied all patients. Therefore, a biomarker assess molecular residual disease (MRD) accurately and guide treatment selection is highly desirable for high-risk This feasibility study evaluated the prognostic value tissue comprehensive genomic profiling (CGP)-informed, personalized circulating...
3521 Background: Postoperative circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) is reported to be associated with a high risk of recurrence. Here, we present an updated analysis and the lead time interval (LTI) ctDNA positivity radiographic recurrence in patients (pts) radically resected colorectal cancer (CRC), stage II-IV observational GALAXY study. Methods: Serial was analyzed using personalized tumor-informed assay (Signatera bespoke multiplex-PCR NGS assay) at 1...
220 Background: Precise monitoring of treatment response may support and improve decision-making in patients with metastatic colorectal cancer (mCRC). The PLCRC-ORCA study aimed to explore the clinical applicability personalized ctDNA testing for mCRC. Methods: prospective, observational ORCA is a substudy Prospective Dutch ColoRectal Cancer cohort (PLCRC). After informed consent, blood samples were collected before initiating first line (baseline) subsequently every 8-9 weeks during routine...
PURPOSE Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication tailoring adjuvant treatments patients resected from a stage III colon cancer (CC). Here, we analyzed the prognostic value of biomarkers who participated randomized phase IDEA-France HORG trials. METHODS Plasma samples were collected after surgery before chemotherapy. ctDNA analysis was performed using clinically validated, personalized, tumor-informed 16-plex protein chain...